{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:26:37Z","timestamp":1767068797106,"version":"3.48.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10637-025-01594-9","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:41:58Z","timestamp":1764855718000},"page":"1222-1234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ABCB1 and ABCC10 polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in EGFR-mutant NSCLC"],"prefix":"10.1007","volume":"43","author":[{"given":"Sanae","family":"Toda-Shiraga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Kakihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Hashiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyasu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Onuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keima","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Fukumitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Oguri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"1594_CR1","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998\u20132006. https:\/\/doi.org\/10.1001\/jama.2014.3741","journal-title":"JAMA"},{"key":"1594_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW (2022) Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 40:611\u2013625. https:\/\/doi.org\/10.1200\/JCO.21.01626","journal-title":"J Clin Oncol"},{"key":"1594_CR3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388. https:\/\/doi.org\/10.1056\/NEJMoa0909530","journal-title":"N Engl J Med"},{"key":"1594_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Mu\u00f1oz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239\u2013246. https:\/\/doi.org\/10.1016\/S1470-2045(11)70393-X","journal-title":"Lancet Oncol"},{"key":"1594_CR5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"key":"1594_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, J\u00e4nne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786\u2013792. https:\/\/doi.org\/10.1056\/NEJMoa044238","journal-title":"N Engl J Med"},{"key":"1594_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA J\u00e4nne","year":"2015","unstructured":"J\u00e4nne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689\u20131699. https:\/\/doi.org\/10.1056\/NEJMoa1411817","journal-title":"N Engl J Med"},{"key":"1594_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"key":"1594_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"1594_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"1594_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L (2015) Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B 5:390\u2013401. https:\/\/doi.org\/10.1016\/j.apsb.2015.07.001","journal-title":"Acta Pharm Sin B"},{"key":"1594_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5438-2","volume":"19","author":"K Sone","year":"2019","unstructured":"Sone K, Oguri T, Uemura T, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A (2019) Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort. BMC Cancer 19:246. https:\/\/doi.org\/10.1186\/s12885-019-5438-2","journal-title":"BMC Cancer"},{"key":"1594_CR13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s10637-022-01275-x","volume":"40","author":"M Horiuchi","year":"2022","unstructured":"Horiuchi M, Uemura T, Oguri T, Toda S, Yamamoto S, Suzuki Y, Kagawa Y, Sone K, Fukuda S, Mori Y, Fukumitsu K, Kanemitsu Y, Tajiri T, Ohkubo H, Takemura M, Ito Y, Maeno K, Niimi A (2022) Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel. Invest New Drugs 40:934\u2013943. https:\/\/doi.org\/10.1007\/s10637-022-01275-x","journal-title":"Invest New Drugs"},{"key":"1594_CR14","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1111\/j.1349-7006.2010.01690.x","volume":"101","author":"T Uemura","year":"2010","unstructured":"Uemura T, Oguri T, Ozasa H, Takakuwa O, Miyazaki M, Maeno K, Sato S, Ueda R (2010) ABCC11\/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci 101:2404\u20132410. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01690.x","journal-title":"Cancer Sci"},{"key":"1594_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djj469","volume":"8","author":"Y Inoue","year":"2019","unstructured":"Inoue Y, Morita T, Onozuka M, Saito KI, Sano K, Hanada K, Kondo M, Nakamura Y, Kishino T, Nakagawa H, Ikegami Y (2019) Impact of Q141K on the transport of epidermal growth factor receptor tyrosine kinase inhibitors by ABCG2. Cells 8:763. https:\/\/doi.org\/10.1093\/jnci\/djj469","journal-title":"Cells"},{"key":"1594_CR16","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/jnci\/djj469","volume":"98","author":"G Cusatis","year":"2006","unstructured":"Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98:1739\u20131742. https:\/\/doi.org\/10.1093\/jnci\/djj469","journal-title":"J Natl Cancer Inst"},{"key":"1594_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00280-010-1533-4","volume":"68","author":"O Takakuwa","year":"2011","unstructured":"Takakuwa O, Oguri T, Ozasa H, Uemura T, Kasai D, Miyazaki M, Maeno K, Sato S (2011) Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Cancer Chemother Pharmacol 68:669\u2013676. https:\/\/doi.org\/10.1007\/s00280-010-1533-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"1594_CR18","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-10-3623","volume":"71","author":"EA Hopper-Borge","year":"2011","unstructured":"Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, Kuang Y, Grinberg A, Westphal H, Chen ZS, Klein-Szanto AJ, Belinsky MG, Kruh GD (2011) Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-\/-) mice. Cancer Res 71:3649\u20133657. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3623","journal-title":"Cancer Res"},{"key":"1594_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-16-0511","volume":"16","author":"H Zhang","year":"2017","unstructured":"Zhang H, Patel A, Wang YJ, Zhang YK, Kathawala RJ, Qiu LH, Patel BA, Huang LH, Shukla S, Yang DH, Ambudkar SV, Fu LW, Chen ZS (2017) The BTK inhibitor ibrutinib (PCI-32765) overcomes paclitaxel resistance in ABCB1- and ABCC10-overexpressing cells and tumors. Mol Cancer Ther 16:1021\u20131030. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0511","journal-title":"Mol Cancer Ther"},{"key":"1594_CR20","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1158\/0008-5472.CAN-04-3303","volume":"65","author":"NB Elkind","year":"2005","unstructured":"Elkind NB, Szentp\u00e9tery Z, Ap\u00e1ti A, Ozvegy-Laczka C, V\u00e1rady G, Ujhelly O, Szab\u00f3 K, Homolya L, V\u00e1radi A, Buday L, K\u00e9ri G, N\u00e9met K, Sarkadi B (2005) Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65:1770\u20131777. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3303","journal-title":"Cancer Res"},{"key":"1594_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"1594_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2789","volume":"10","author":"JI Fletcher","year":"2010","unstructured":"Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10:147\u2013156. https:\/\/doi.org\/10.1038\/nrc2789","journal-title":"Nat Rev Cancer"},{"key":"1594_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1389200043489199","volume":"5","author":"A Haimeur","year":"2004","unstructured":"Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP-related and BCRP\/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21\u201353. https:\/\/doi.org\/10.2174\/1389200043489199","journal-title":"Curr Drug Metab"},{"key":"1594_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/00498250600861751","volume":"36","author":"K Bleasby","year":"2006","unstructured":"Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, Slatter JG (2006) Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963\u2013988. https:\/\/doi.org\/10.1080\/00498250600861751","journal-title":"Xenobiotica"},{"key":"1594_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/jpet.110.167601","volume":"334","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147\u2013155. https:\/\/doi.org\/10.1124\/jpet.110.167601","journal-title":"J Pharmacol Exp Ther"},{"key":"1594_CR26","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1349-7006.2009.01213.x","volume":"100","author":"K Noguchi","year":"2009","unstructured":"Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y (2009) Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci 100:1701\u20131707. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01213.x","journal-title":"Cancer Sci"},{"key":"1594_CR27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/1535-7163.MCT-15-0939","volume":"15","author":"Z Chen","year":"2016","unstructured":"Chen Z, Chen Y, Xu M, Chen L, Zhang X, To KK, Zhao H, Wang F, Xia Z, Chen X, Fu L (2016) Osimertinib (AZD9291) enhanced the efficacy of chemotherapeutic agents in ABCB1- and ABCG2-overexpressing cells in vitro, in vivo, and ex vivo. Mol Cancer Ther 15:1845\u20131858. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0939","journal-title":"Mol Cancer Ther"},{"key":"1594_CR28","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1007\/s10637-022-01304-9","volume":"40","author":"H Yokota","year":"2022","unstructured":"Yokota H, Sato K, Sakamoto S, Okuda Y, Fukuda N, Asano M, Takeda M, Nakayama K, Miura M (2022) Effects of CYP3A4\/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Invest New Drugs 40:1254\u20131262. https:\/\/doi.org\/10.1007\/s10637-022-01304-9","journal-title":"Invest New Drugs"},{"key":"1594_CR29","first-page":"5749","volume":"62","author":"AE Wakeling","year":"2002","unstructured":"Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749\u20135754","journal-title":"Cancer Res"},{"key":"1594_CR30","first-page":"4838","volume":"57","author":"JD Moyer","year":"1997","unstructured":"Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838\u20134848","journal-title":"Cancer Res"},{"key":"1594_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046\u20131061. https:\/\/doi.org\/10.1158\/2159-8290","journal-title":"Cancer Discov"},{"key":"1594_CR32","unstructured":"National Center for Biotechnology Information (2024) rs1128503 RefSNP report. In dbSNP. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/snp\/rs1128503"},{"key":"1594_CR33","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K, FLAURA2 Investigators (2023) Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 389:1935\u20131948. https:\/\/doi.org\/10.1056\/NEJMoa2306434","journal-title":"N Engl J Med"},{"key":"1594_CR34","unstructured":"National Center for Biotechnology Information (2024) Rs2125739 RefSNP report. https:\/\/www.ncbi.nlm.nih.gov\/snp\/rs2125739"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01594-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:25:28Z","timestamp":1767068728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01594-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01594-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Nagoya City University (No. 70\u201300-0095).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}